Immunosuppressive drugs.
The success rate of clinical transplantation has improved considerably over the last two decades largely due to better immunosuppressive drugs. Allograft rejection remains the major cause of graft loss in renal transplant recipients. This article reviews the mechanisms of action of immunosuppressive drugs and their clinical use.
D000818:Animals; D001379:Azathioprine / Q000494:pharmacology / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D003524:Cyclosporins / Q000494:pharmacology / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000494:pharmacology / Q000627:therapeutic use; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D016559:Tacrolimus / Q000494:pharmacology / Q000627:therapeutic use
D003524:Cyclosporins; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus; D008727:Methotrexate